AMBA vs ASGN

Ambarella (AMBA) exhibits weak financial health per the Piotroski F-Score of 4/9, indicating a fragile operational foundation despite modest growth. The company trades at a high forward P/E of 48.14 and a price/sales ratio of 5.76, significantly above sector averages, suggesting overvaluation. While revenue growth is strong at 20.1% YoY and earnings surprises have been positive in recent quarters, profitability remains deeply negative with a -19.42% profit margin and negative ROE/ROA. Insider selling activity totaling $6.52M over six months signals bearish sentiment from within the company. The absence of a Graham Number and intrinsic value estimate further limits fundamental valuation clarity.

ASGN exhibits strong financial health with a Piotroski F-Score of 7/9, indicating solid operational and balance sheet fundamentals. The company trades near fair value based on the Graham Number of $52.86, with a current price of $51.04, while forward P/E of 10.26 suggests discounted earnings expectations. Despite healthy margins and a strong balance sheet (Current Ratio 1.99, Debt/Equity 0.68), revenue and earnings are contracting YoY (-1.90% and -17.90% respectively), offsetting valuation appeal. Analysts concur with a 'hold' rating and target price of $51.17, aligning closely with current levels.